Skip to main content
    G

    Genmab AS (GMAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $51.57
    +0.20 (+0.39%)

    Market Cap: $31.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Genmab AS (GMAB) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Genmab AS are BeOne Medicines AG (ONC), argenx NV ADR (ARGX) and Insmed (INSM). Genmab AS trades at 35.8x earnings, against a median of 19.3x for the 5 of these companies with a P/E. By market cap, Genmab AS ranks 6th of the 13 companies on this page; Moderna (MRNA) is the largest at $90.38B.

    Peer Comparison

    GMAB's ROIC of 4.8% is above the peer median of -12.7%, and its revenue growth of 16.1% is below the median of 43.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Genmab AS (GMAB)$31.67B35.8x19.2x17.0%4.8%16.1%0.00%
    BeOne Medicines AG (ONC)$47.58B50.0x18.7x13.9%7.5%33.8%0.00%
    argenx NV ADR (ARGX)$60.37B33.5x6.1x31.7%N/A52.1%0.00%
    Insmed Inc (INSM)$26.58BN/A17.7x-39.9%-44.2%268.4%0.00%
    Ascendis Pharma AS (ASND)$18.06BN/A13.5x72.9%12.4%73.0%0.00%
    Revolution Medicines Inc (RVMD)$37.27BN/A181.6x0.0%-52.1%-95.2%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Exelixis Inc (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    Roivant Sciences Ltd (ROIV)$28.64BN/A679.3x0.0%N/A2136.0%0.00%
    Moderna Inc (MRNA)$90.38BN/A34.2x-110.5%-28.9%29.2%0.00%
    Jazz Pharmaceuticals PLC (JAZZ)$15.50B18.4x3.3x4.4%3.5%10.4%0.00%
    Royalty Pharma Plc (RPRX)$39.85B12.9x11.7x25.7%7.6%13.3%1.37%
    Kymera Therapeutics Inc (KYMR)$10.89BN/A123.2x0.0%N/A466.4%0.00%
    Peer median$27.61B19.3x16.9x2.2%-12.7%43.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Genmab AS, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    BeOne Medicines AG (ONC)
    BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe...
    ONC competitors
    argenx NV ADR (ARGX)
    argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases...
    ARGX competitors
    Insmed Inc (INSM)
    Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases.
    INSM competitors
    Ascendis Pharma AS (ASND)
    Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
    ASND competitors
    Revolution Medicines Inc (RVMD)
    Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted...
    RVMD competitors
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    Exelixis Inc (EXEL)
    Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development...
    EXEL competitors
    Roivant Sciences Ltd (ROIV)
    Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive...
    ROIV competitors
    Moderna Inc (MRNA)
    Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology...
    MRNA competitors
    Jazz Pharmaceuticals PLC (JAZZ)
    Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United...
    JAZZ competitors
    Royalty Pharma Plc (RPRX)
    Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States.
    RPRX competitors
    Kymera Therapeutics Inc (KYMR)
    Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down...
    KYMR competitors

    Frequently Asked Questions About GMAB

    Who are Genmab AS' main competitors?

    The companies most similar to Genmab AS include BeOne Medicines AG (ONC), argenx NV ADR (ARGX), Insmed (INSM), Ascendis Pharma AS (ASND) and Revolution Medicines (RVMD), listed from the closest match.

    Who is Genmab AS' biggest competitor?

    Moderna (MRNA) is the largest of the similar companies at $90.38B; BeOne Medicines AG (ONC) is the closest match by business profile, size, sector and industry.

    How does GMAB stock compare with its competitors?

    GMAB's P/E is 35.8x against a peer median of 19.3x; its P/S is 19.2x against a peer median of 16.9x; its net margin is 17.0% against a peer median of 2.2%.

    Which of Genmab AS' competitors pays a higher dividend?

    Genmab AS pays no dividend. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.

    Is Genmab AS bigger than its competitors?

    No. Genmab AS is 6th by market cap among the 13 companies on this page; the largest is Moderna (MRNA) at $90.38B.